Plasbumin-5 market forecast points to growth in critical care and surgery

The Plasbumin-5 market is expanding on rising surgical volumes, burn cases, and broader critical care use, according to a new report from The Business Research Company. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through 2035.

Why it matters: - Plasbumin-5 is used to restore blood volume in patients with major fluid loss, so demand tracks with critical care need, surgery volume, and emergency treatment. - The market outlook matters to healthcare suppliers and investors because growth is tied to ICU expansion, plasma collection capacity, and adoption in liver and cardiac care.

What happened: - The Business Research Company released its Plasbumin-5 Market Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report points to rising demand for Plasbumin-5 across hospitals and other acute care settings. - The report includes a free sample at Download a free sample of the Plasbumin-5 market report. - The full report is available at View the full plasbumin-5 market report.

The details: - Plasbumin-5 is a sterile human plasma-derived albumin solution used as a volume expander for patients who have lost significant fluids. - The therapy helps restore blood volume, stabilize blood pressure, and transport essential substances through the body. - Market growth has been driven by more hypovolemia and shock cases, more surgical procedures, advances in plasma fractionation, growth in critical care infrastructure, and wider use of albumin in emergency care. - The report expects further growth from stronger demand for plasma-derived therapies, more patient blood management programs, expansion of ICU capacity, and greater use in liver and cardiac care. - The report also highlights higher use of plasma-derived volume expanders, stronger demand for albumin therapy in critical care, broader use in surgeries and intensive care units, development of high-purity albumin products, and a focus on maintaining hemodynamic stability. - Surgical procedures are a major driver because Plasbumin-5 supports blood volume, blood pressure, tissue perfusion, hypoproteinemia management, and post-operative healing. - The British Association of Aesthetic Plastic Surgeons reported 27,462 cosmetic surgeries in the UK in 2024, up 5% year over year. - Burn injuries are another growth driver because Plasbumin-5 helps replenish blood volume, sustain circulatory pressure, elevate protein levels, reduce edema risk, and support recovery. - The American Burn Association reported 32,540 burn cases in 2023, up from 30,135 in 2022, with 156,073 cases over five years. - In 2025, North America held the largest share of the Plasbumin-5 market. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. - The 2026 edition adds market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, and updated graphics and tables.

Between the lines: - The report frames Plasbumin-5 as a niche but defensive market, with demand linked to essential clinical use rather than elective spending alone. - Rising surgical volumes and burn incidence suggest the market is benefiting from multiple care pathways, not a single end-use segment. - The regional split signals a mature North American base and faster expansion in markets investing in critical care capacity.

What's next: - Growth will likely depend on how quickly hospitals expand ICU capacity and how broadly plasma-derived therapies are adopted in critical care. - Investments in plasma collection networks could become a key supply-side factor supporting future expansion. - The report points to continued momentum through 2035 as clinical demand and infrastructure build-out continue.